Phase:Demo Project
Principal Investigator(s):Beatriz Grinsztejn
Objective:Assess the acceptability, feasibility and safety of daily, oral TDF/FTC as PrEP over 12 months.
Prevention Option(s):PrEP
Study Design:Open label, Uncontrolled
Arms and Assigned Interventions
DescriptionFixed dose combination of emtricitabine (FTC) / tenofovir (TDF) (200/300 mg) once daily orally.
Mode of DeliveryTablet
Official Code: NCT01989611
Trial Sponsors: University of Sao Paulo; Centro de Referência e Treinamento DST AIDS; Oswaldo Cruz Foundation
Start Date
End Date
January 31, 2014
January 31, 2016
Age range: 18 Years ↔ any
Population:Cisgender Women, Gay and Bisexual Men Who Have Sex with Men